Quantitative tests (QLFTS) detect impaired hepatic function in a high proportion of chronic hepatitis C patients with fibrosis or compensated cirrhosis and may predict risk of cirrhosis, splenomegaly, and varices.

被引：0

作者：

Everson, GT

Kugelmas, M

DeSanto, J

Lauriski, S

Shiffman, ML

Sterling, R

Charlotte, H

Morgan, T

Hoefs, J

Milne, N

Rietkerk, W

Wagner, D

Wright, E

机构：

[1] Univ Colorado, Sch Med, Denver, CO 80202 USA

[2] Virginia Commonwealth Univ, Richmond, VA USA

[3] Univ Calif Irvine, Irvine, CA 92717 USA

[4] Metabol Solut, Nashua, NH USA

[5] New England Res Inst, Watertown, MA 02172 USA

来源：

HEPATOLOGY | 2003年 / 38卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

309

引用

页码：304A / 305A

页数：2

共 8 条

[1] Simple blood tests can predict compensated liver cirrhosis in patients with chronic hepatitis C
Luo, JC
Hwang, SJ
Chang, FY
Chu, CW
Lai, CR
Wang, YJ
Lee, PC
Tsay, SH
Lee, SD
HEPATO-GASTROENTEROLOGY, 2002, 49 (44) : 478 - 481
[2] Impaired glucose metabolism increases risk of hepatic decompensation and death in patients with compensated hepatitis C virus-related cirrhosis
Calzadilla-Bertot, Luis
Vilar-Gomez, Eduardo
Torres-Gonzalez, Ana
Socias-Lopez, Maray
Diago, Moises
Adams, Leon A.
Romero-Gomez, Manuel
DIGESTIVE AND LIVER DISEASE, 2016, 48 (03) : 283 - 290
[3] HEPATIC IMPAIRMENT MEASURED BY QUANTITATIVE TESTS OF LIVER FUNCTION (QLFTS) PREDICTS CLINICAL OUTCOME IN PATIENTS WITH ADVANCED FIBROSIS: RESULTS FROM THE HEPATITIS C ANTIVIRAL LONG-TERM TREATMENT AGAINST CIRRHOSIS (HALT-C) TRIAL
Everson, Gregory T.
Hoefs, John C.
Shiffman, Mitchell L.
Morgan, Timothy R.
Sterling, Richard K.
Curto, Teresa M.
Wagner, David
Wright, Elizabeth C.
Everhart, James E.
HEPATOLOGY, 2009, 50 (04) : 1057A - 1058A
[4] CAN NON-INVASIVE TESTS (NIT) DETECT CHANGES IN HEPATIC VENOUS PRESSURE GRADIENT (HVPG) IN PATIENTS WITH HEPATITIS C (HCV) COMPENSATED CIRRHOSIS?
Ortiz, Guillermo
Mohanty, Arpan
Sayyar, Mubarak
Jangouk, Parastoo
Gunabushanam, Gowthaman
Sheldon, Campbell
Deng, Yanhong
Ciarleglio, Maria
Garcia-Tsao, Guadalupe
HEPATOLOGY, 2019, 70 : 1237A - 1237A
[5] A cirrhosis risk score identifies those chronic hepatitis C infected patients presenting with no liver fibrosis that are at high risk for fibrosis progression
Young, Bradford
Gerotto, Martina
Morcolongo, Moira
Dal Pero, Francesca
Lagier, Robert
Rowland, Charles
Sebastiani, Giodo
Alberti, Alfredo
Alameda, Celera
HEPATOLOGY, 2007, 46 (04) : 442A - 443A
[6] Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis
Hsieh, Yi-Chung
Jeng, Wen-Juei
Huang, Chien-Hao
Teng, Wei
Chen, Wei-Ting
Chen, Yi-Cheng
Lin, Shi-Ming
Tai, Dar-In
Lin, Chun-Yen
Sheen, I-Shyan
PLOS ONE, 2018, 13 (08):
[7] Long-term fibrosis improvement after sustained virologic response in patients with chronic hepatitis C and advanced fibrosis or cirrhosis - pre-treatment cirrhosis, older age and high body mass index increases the risk for persisting fibrosis
Hedenstierna, M.
Nangarhari, A.
Weiland, O.
Aleman, S.
JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S493 - S494
[8] HIGH DOSE VITAMIN D SUPPLEMENTATION IN GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS WITH ADVANCED FIBROSIS/COMPENSATED CIRRHOSIS NON RESPONDERS TO PREVIOUS STANDARD THERAPY: RESULTS OF THE HEP-D3 STUDY
Almerighi, Cristiana
Franceschelli, Antonella
Francioso, Simona
Forte, Paolo
Nosotti, Lorenzo
Salso, Angela
De Leonardis, Francesco
Telese, Andrea
Angelico, Mario
HEPATOLOGY, 2011, 54 : 857A - 858A

← 1 →